ArticleInternational journal of cancer2020

CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab.

Roberto Arriga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.